Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longzhong Xiaozhong Zhitong Heji (陇中消肿止痛合剂) is a traditional Chinese medicine compound preparation used primarily for the treatment of soft tissue injuries, osteofascial compartment syndrome, and acute traumatic synovitis of the knee. It is formulated as an oral liquid and contains multiple herbal ingredients with purported effects such as reducing swelling, relieving pain, promoting blood circulation, and accelerating recovery from trauma. Clinical studies have shown that it can reduce serum markers of muscle damage (CK), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) in patients with closed soft tissue injuries[1][2][3][9]. In osteofascial compartment syndrome patients, it has been observed to improve pain scores and laboratory indicators when used alongside standard therapy[2][4]. The mechanism of action is believed to involve anti-inflammatory effects, reduction of edema, promotion of microcirculation repair, and facilitation of wound healing through multi-target modulation typical for complex herbal mixtures[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longzhong Xiaozhong Zhitong Heji.